2C-B: Overview
2C-B (also known as nexus, venus, bees, or 4-bromo-2,5-dimethoxyphenethylamine) is a psychedelic drug belonging to the phenethylamine class, which includes MDMA and mescaline. 2C-B is a member of the 2C-X series or 2C family, known for its empathogenic and psychedelic effects. It is particularly noted for its ability to increase sexual arousal, making it popular as an aphrodisiac.
History
2C-B was first synthesized in 1974 by Alexander Shulgin, who detailed its synthesis in his book “Phenethylamines I Have Known and Loved” (PiHKAL). It gained popularity in the rave and dance music scene in the mid-1980s as a legal substitute for MDMA, although it has since been criminalized in many countries.
Consumption
2C-B is primarily taken orally as a powder or in tablet form. It can also be snorted, but this method is considered painful by users. Due to the potential for adulteration, testing 2C-B with a reagent test kit is recommended to ensure its purity.
Effects
The effects of 2C-B vary based on dosage and individual response, often depending on the user’s mindset and environment. Commonly reported effects include:
- Enhanced touch sensation and music appreciation
- Enhanced visual sensation and color vibrancy
- Altered perception of space and time
- Giggling and laughter
- Visual and auditory hallucinations
- Mood lift and euphoria
- Increased sex drive
- Profound religious and mystical experiences
Dosing
It is advisable to start at a low dose and wait before redosing. A rough dosage guide for 2C-B is as follows:
- Low Dose: 5-15 mg
- Moderate Dose: 15-25 mg
- Strong Dose: 25-40 mg
- Heavy Dose: 40+ mg
2C-B is a unique psychedelic with a rich history and a variety of effects, making it a popular choice among those exploring altered states of consciousness.
Pills | 10 Pills, 50 Pills, 100 Pills, 200 Pills, 500 Pills, 1000 Pills |
---|
Only logged in customers who have purchased this product may leave a review.
Related products
Psychedelics
Psychedelics
Psychedelics
Psychedelics
Reviews
There are no reviews yet.